Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

50
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
50
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

47
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
47
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

4.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.8K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.4K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of levodopa on the blood antioxidant system and metabolome in patients with Parkinson's disease.

Biomeditsinskaia khimiia·2026
Same author

[Assessment of the rationality of pharmacotherapy in elderly patients with acute coronary syndrome using geriatric scales.]

Advances in gerontology = Uspekhi gerontologii·2026
Same author

[Associations of polymorphic variants of CYP2C19*2, *17 with effectiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

The Effectiveness and Profitability of Different Antithrombotic Therapy Regimens in Patients with Type 2 Diabetes Mellitus During 1 Year of Follow-Up after an Exacerbation of Coronary Heart Disease According to the Study ORACLE II.

Kardiologiia·2025
Same author

[Features of clinical and laboratory parameters in elderly patients with acute coronary syndrome.]

Advances in gerontology = Uspekhi gerontologii·2025
Same author

Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study.

Pharmacogenomics·2025

Related Experiment Video

Updated: Mar 8, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.8K

[Polypragmasy: A clinical pharmacologist's view].

D A Sychev1, V A Otdelеnov2, N M Krasnova3

  • 1Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow, Russia.

Terapevticheskii Arkhiv
|February 1, 2017
PubMed
Summary

Polypragmasy, the use of multiple medications, is a significant public health issue causing reduced treatment effectiveness and increased healthcare costs. Strategies like the Beers and STOPP/START criteria can minimize polypragmasy, especially in elderly patients, improving pharmacotherapy safety and efficiency.

Area of Science:

  • Pharmacology
  • Geriatrics
  • Public Health

Background:

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.8K

Related Experiment Videos

Last Updated: Mar 8, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.8K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.8K
  • Polypragmasy, or the concurrent use of numerous medications, is a growing concern in modern healthcare.
  • It arises from factors like comorbidity, drug availability, and treatment guidelines, leading to reduced pharmacotherapy effectiveness and increased healthcare expenses.
  • Polypragmasy is a major risk factor for adverse drug reactions, particularly in elderly populations.